Isoxsuprine in the treatment of sickle cell painful crises: A double-blind comparative study with narcotic analgesic

Annals of Saudi Medicine

Volumn 19, Issue 2, 1999, Pages 97-100

  Al Jam'a, Ali H ^a   Al Dabbous, Ibrahim A ^a   Rafiq, Muhammad S ^a   Al Khatti, Adil ^a   Al Salem, Ahmed H ^a   Al Baharna, Abdalali ^a   Boholaiga, Mohammed ^a  

^a NONE

Author keywords

Isoxsuprine; Painful crisis; Sickle cell disease

Indexed keywords

ISOXSUPRINE; PETHIDINE;

ADOLESCENT; ADULT; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HOSPITAL ADMISSION; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; LENGTH OF STAY; MALE; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SICKLE CELL ANEMIA; SIDE EFFECT;

EID: 0032820498     PISSN: 02564947     EISSN: None     Source Type: Journal    
DOI: 10.5144/0256-4947.1999.97     Document Type: Article

References (22)

1. Lukes JN. Hemoglobinopathies. In: Wintrobe's Clinical Hematology. 9th edition (Indian edition). Philadelphia: Lea & Febiger, 1993;38:1061-101.
2. Ballas SK. The sickle painful crisis in adults: phases and objective signs. Hemoglobin 1995;19:323-33.
3. Diggs LW. Sickle cell crises. Am J Clin Pathol 1965;44:1.
4. Platt OS. Easing the suffering caused by sickle cell disease (editorial). New Engl J Med 1994;330:783-4.
5. Vickinsky EP, Johnson R, Lubin BH. Multidisciplinary approach to pain management in sickle cell disease. Am J Pediat Hematol/Oncol 1982;4:328-33.
6. Psomadakis C, Kallerghi G, Bourantas C, Papageorgious J. Experience with isoxsuprine in the treatment of sickle cell crisis: a proposed mechanism of action. Angiology 1981;32:249-56.
7. Serjeant GR, Howard C. Isoxsuprine hydrochloride in the therapy of sickle cell leg ulceration. West Indian Med J 1977;26:164-6.
8. BMDP Statistical Software Version 1990. BMDP Statistical Software Inc., Sepulveda Blvd, Cork Technology Park, Model Farm Rd, LA Ca 90025, USA.
9. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease: rates and risk factors. N Eng J Med 1991;325:11-16.
10. Harris JW, Brewster HH, Ham HT, Castle WB. Studies on the destruction of red cells: the biophysics and biology of sickle cell disease. Arch Int Med 1956;97:145.
11. Hebbel RP. Beyond hemoglobin polymerization: the red blood cell membrane and sickle cell disease pathophysiology. Blood 1991;77:214-37.
12. Hebbel RP, Schwartz RS, Mohandas N. The adhesive sickle cell erythrocyte: cause and consequence of abnormal interaction with endothelium, monocyte/macrophages and model membranes. Clin Haematol 1985;14:141.
13. Benjamin LJ, Berkowitz LR, Orringer E, Mankad VN, Prasad AS, Lewkow LM, et al. A collaborative, double-blind randomized study of cetiedil citrate in sickle cell crisis. Blood 1986;67:1442-7.
14. Alkhatti A. Experimental therapy of sickle cell disease. In: Al-Jam'a AH, Al-Dabbous IA, editors. Management manual of sickle cell disease. Dammam: Al-Shati Modern Press, 1992:247-54.
15. Griffin TC, McIntire D, Buchanan GR. High-dose intravenous methyl prednisolone therapy for pain in children and adolescents with sickle cell disease. New Engl J Med 1994;330:733-34.
16. Aarts PAMM, Heethar RM, Sixma JJ. Red blood cell deformability influences platelet-vessel wall interaction in flowing blood. Blood 1984;64:1228-33.
17. Aarts PAMM, Banga JD, van Houwelingen HC, Heethar RM, Sixma II. Red blood cell deformability due to isoxsuprine administration decreases platelet adherence in a perfusion chamber: a double-blind cross-over study in patients with intermittent claudication. Blood 1986;67:1474-81.
18. Bode WA. Effects of long-term treatment with isoxsuprine on the blood viscosity profile in maturity onset diabetics. Clin Hemorheol 1982;2:189-93.
19. Di Perri T, Forconi S, Agnusdei D, Guerrini M, Laghi Pasinin F. The effects of intravenous isoxsuprine on blood viscosity in patients with occlusive peripheral arterial disease. Br J Clin Phramacol 1978;5:255.
20. Skitnicki SH, van Gaal G, Wijn PFF. The effectiveness of isoxsuprine in patients with intermittent claudication. Angiology 1984;35:685-93.
21. Kaindl F, Samuels SS, Selman D, Shaftel H. A new vasodilating andantispasmodic agent: isoxsuprine-HCl. Angiology 1959;10:185.
22. Dhrymiotis AD, Whittier JR. Effect of a vasodilator, isoxsuprine on cerebral ischemic episodes. Curr Ther Res 1962;4:124.